Marker Therapeutics (NASDAQ:MRKR) Issues Earnings Results

Marker Therapeutics (NASDAQ:MRKR) posted its quarterly earnings results on Friday. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.16, Zacks reports. Marker Therapeutics had a negative return on equity of 73.29% and a negative net margin of 343.03%.

Marker Therapeutics Stock Up 2.7%

NASDAQ:MRKR traded up $0.03 during trading hours on Friday, reaching $1.14. 45,559 shares of the stock were exchanged, compared to its average volume of 46,148. The stock has a market capitalization of $19.01 million, a P/E ratio of -1.87 and a beta of 1.50. The firm has a 50 day simple moving average of $1.32 and a 200-day simple moving average of $1.42. Marker Therapeutics has a 52 week low of $0.81 and a 52 week high of $2.46.

Institutional Investors Weigh In On Marker Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC bought a new stake in shares of Marker Therapeutics during the fourth quarter valued at about $60,000. Geode Capital Management LLC increased its stake in Marker Therapeutics by 35.3% during the 4th quarter. Geode Capital Management LLC now owns 130,344 shares of the company’s stock valued at $194,000 after buying an additional 34,028 shares during the period. NewEdge Advisors LLC bought a new stake in shares of Marker Therapeutics during the 4th quarter worth about $222,000. Renaissance Technologies LLC lifted its stake in shares of Marker Therapeutics by 16.4% in the 4th quarter. Renaissance Technologies LLC now owns 123,650 shares of the company’s stock worth $184,000 after acquiring an additional 17,400 shares during the period. Finally, Osaic Holdings Inc. increased its stake in shares of Marker Therapeutics by 16.5% during the fourth quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock valued at $141,000 after acquiring an additional 13,340 shares during the period. 22.39% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Marker Therapeutics in a research note on Wednesday, May 20th. Weiss Ratings downgraded Marker Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 6th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $10.00.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.